PSI Medical Statistics Careers Event
This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
Core Committee (L-R): Fetene Tekle (Janssen), Gareth Thomas (former member and chair), Bernd Igl (Boehringer Ingelheim), Eloisa Brook (chair, GlaxoSmithKline), Jim Saul (former member, Covance) and Phillip Jarvis (former member, Novartis). Luc Essermeant (Sanofi), Ezgi Tanriver-Ayder (GlaxoSmithKline), Sarah Vandepaer (GlaxoSmithKline), Dorothee Tamarelle (Sanofi) and Denise Federico (Evotec) have also joined the team.
To provide a forum to discuss and advance statistical topics related to Research, Discovery (including efficacy models), Regulatory and Investigative Toxicology/Safety Assessment and to promote the involvement of Statisticians in these areas.
Our membership consists of statisticians at CROs, pharmaceutical companies and academia who are working in preclinical (animal and cell based experiments) areas such as:
- Discovery
- Good statistical practice in in-vitro, ex-vivo and in-vivo assay development
- Reproducibility and Translation from pre-clinical to clinical
- Toxicogenomics
- Genetic Toxicology
- Acute Toxicology
- General Toxicology
- Eco-Toxicology
- Toxicokinetics
- DMPK / Pharmacokinetics
- ECG
- Immuno Toxicology
- Histopathology
- Pharmacology
- Developmental and Reproductive Toxicology
- Carcinogenicity
We discuss diverse topics ranging from Dog Telemetry data analysis to Decision Trees, from Bayesian methods to dealing with irate study directors, and now have a list of over 50 affiliates on our e-mail distribution list.
Find out more in our video overview:
The PSI Pre-clinical Special Interest Group have a series of regular FREE webinars dealing with statistical topics faced in pre-clinical and related fields. The presentations will run for an hour, with approximately 45 min presentation and a Q&A session in the remaining time. See section below for details of this year’s webinars. Please note that these events take place online via Zoom, and has a limited number of places available.
The PSI Pre-Clinical Special Interest Group seminars for 2023 are as follows:
Date | Title | Presenter | |
14 March 2023 | End-user Tool for Immunogenicity Cut-points Calculation | Dr. Els Pattyn, Ablynx | To access the video on demand, please click here |
27 June 2023 | EC50 Estimation based on Multi-Donor Dose-Response Data | Dr. Weiliang Qiu and Dr. Cheng Wenren, Sanofi | To access the video on demand, please click here |
24 October 2023 | Adjusting Experimental and Statistical Approaches throughout Preclinical Development Pathways | PD Dr. Ulf Tölch, Berlin Institute of Health at Charité | For more information and to register, please click here |
Please email us with any questions or comments and if you would like to join our mailing list.
This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Over the course of two sessions, a panel of 8 esteemed speakers will give an introduction to the topic, followed by a presentation of case studies & interactive panel discussion.
Over the past years, areas of clinical development and patient access / health technology assessment (HTA) have moved closer together. However, both areas differ in how they approach their respective research or policy questions. While the estimand framework is being the focus in clinical development, HTA is being viewed through the lens of the PICO framework. This webinar brings together Antonio Remiro-Azocar, Robert Hemmings and Nicholas Latimer, who are renowned experts in the respective fields. They will provide an introduction to these three concepts, illustrated with examples.
In a world buzzing with artificial intelligence, can you distinguish between what's AI-generated and what's not? The session promises to showcase machine-generated content, challenging your perceptions, and luring you into the fascinating world of AI technology.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This course consists of 5 x 2 hour training sessions run over 5 weeks. For those who cannot attend the date and time provided, there will be a recording provided and a follow-up 1 hour Q and A session. Participation will provide access to extensive course materials in the form of a “bookdown” site. However, this is designed as a hands-on, interactive course. Both you and the trainers will work entirely within the RStudio Cloud development environment, which will remain accessible between virtual sessions in order to further explore and cement your understanding.
The Pre-Clinical SIG Workshop returns for 2024, bringing you a two half-days event, starting with a course on pre-clinical design of experiments. We will also have speakers on topics such as statistics and genetic toxicology, the new and promising OMARS DOE and ANOVA-type.
Are you a member of PSI looking to further your career or help develop others - why not sign up to the PSI Mentoring scheme? You can expand your network, improve your leadership skills and learn from more senior colleagues in the industry.
Suitable for PhD candidates in statistics or a related discipline. Full-time for 10-12 weeks in Summer 2024. Remote working, from the United States or the United Kingdom
The Principal DMC Statistician works primarily in the production and quality control.
Head of Respiratory Vaccines Clinical Statistics role has portfolio leadership for statisticians aligned to vaccine development in the area of Respiratory disease, providing statistical leadership for Clinical Development and Commercialization.
BioMarin is the world leader in delivering therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases.